Esophageal atresia and prenatal exposure to mycophenolate

Reproductive Toxicology

Volumn 50, Issue , 2014, Pages 117-121

  Martin M C ^a,f   Cristiano, E ^b,f   Villanueva, M ^c   Bonora, M L ^d,f   Berguio, N ^d,f   Tocci, A ^e,f   Groisman, B ^a,f   Bidondo, M P ^a,f   Liascovich, R ^a,f   Barbero, P ^a,f  

^a National Center of Medical Genetics Dr Eduardo Castilla   (Argentina)

^b Hospital Penna   (Argentina)

^c Hospital Pedro Elizalde   (Argentina)

^d University of Rio Cuarto   (Argentina)

^e HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^f National Registry of Congenital Anomalies of Argentina (RENAC)   (Argentina)

Author keywords

Drug induced abnormalities; Esophageal atresia; Mycophenolate mofetil; Teratogen

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

ADULT; ARTICLE; CASE REPORT; CHILD; CLEFT LIP PALATE; CLINICAL EXAMINATION; CONGENITAL MALFORMATION; CRANIOFACIAL MALFORMATION; EMBRYOPATHY; ESOPHAGUS ATRESIA; EYE MALFORMATION; FEMALE; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HEART DISEASE; HUMAN; HYDRAMNIOS; MICROTIA; MOUTH MALFORMATION; NEWBORN; PRENATAL DRUG EXPOSURE; SPONTANEOUS ABORTION; TERATOGENICITY; TRACHEOESOPHAGEAL FISTULA; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED;

ADULT; ESOPHAGEAL ATRESIA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID;

EID: 84910055637     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2014.10.015     Document Type: Article

References (28)

1. Sfeir R., Michaud L., Salleron J., Gottrand F. Epidemiology of esophageal atresia. Dis Esophagus 2013, 26:354-355.
2. Pinheiro P.F., Simões e Silva A.C., Pereira R.M. Current knowledge on esophageal atresia. World J Gastroenterol 2012, 18:3662-3672.
3. Oddsberg J. Environmental factors in the etiology of esophageal atresia. J Pediatr Gastroenterol Nutr 2011, 52(Suppl. 1):S4-S5.
4. Roche Laboratories Important changes in the CellCept [mycophenolate mofetil] prescribing information. Use of CellCept is associated with increased pregnancy loss and congenital malformations/change from pregnancy category C to pregnancy category D 2007, Available at: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM154077.pdf.
5. Eckardt K., Stahlmann R. Use of two validated in vitro tests to assess the embryotoxic potential of mycophenolic acid. Arch Toxicol 2010, 84:37-43.
6. Schmidt F., Eckardt K., Shakibaei M., Glander P., Stahlmann R. Effects of mycophenolic acid alone and in combination with its metabolite mycophenolic acid glucuronide on rat embryos in vitro. Arch Toxicol 2013, 87:361-370.
7. Lin A.E., Singh K.E., Strauss A., Nguyen S., Rawson K., Kimonis V.E. An additional patient with mycophenolate mofetil embryopathy: cardiac and facial analyses. Am J Med Genet A 2011, 155:748-756.
8. Hoeltzenbein M., Elefant E., Vial T., Finkel-Pekarsky V., Stephens S., Clementi M., et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A 2012, 158:588-596.
9. Källén B., Westgren M., Aberg A., Otterblad Olaussond P. Pregnancy outcome after maternal organ transplantation in Sweden. BJOG 2005, 112:904-909.
10. Schoner K., Steinhard J., Figiel J., Rehder H. Severe facial clefts in acrofacial dysostosis: a consequence of prenatal exposure to mycophenolate mofetil?. Obstet Gynecol 2008, 111:483-486.
11. Parisi M.A., Zayed H., Slavotinek A.M., Rutledge J.C. Congenital diaphragmatic hernia and microtia in a newborn with mycophenolate mofetil (MMF) exposure: phenocopy for Fryns syndrome or broad spectrum of teratogenic effects?. Am J Med Genet A 2009, 149:1237-1240.
12. Groisman B., Bidondo M.P., Gili J.A., Barbero P., Liascovich R. Strategies to achieve sustainability and quality in birth defects registries: the experience of the national registry of congenital anomalies of Argentina. J Regist Manag 2013, 40:29-31.
13. Merlob P., Stahl B., Klinger G. Tetrada of the possible mycophenolate mofetil embryopathy: a review. Reprod Toxicol 2009, 28:105-108.
14. Ang G.S., Simpson S.A., Reddy A.R. Mycophenolate mofetil embryopathy may be dose and timing dependent. Am J Med Genet A 2008, 146:1963-1966.
15. Ioannides A.S., Copp A.J. Embryology of oesophageal atresia. Semin Pediatr Surg 2009, 18:2-11.
16. Menegola E., Broccia M.L., Di Renzo F. Teratogenic effects of doxorubicin in rats at midgestation and at term. Teratog Carcinog Mutagen 2001, 21:283-293.
17. Cullinane C., Cutts S.M., Panousis C., Phillips D.R. Interstrand cross-linking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells. Nucleic Acids Res 2000, 28:1019-1025.
18. McLaughlin D., Hajduk P., Murphy P., Puri P. Adriamycin-induced models of VACTERL Association. Mol Syndromol 2013, 4:46-62.
19. Domhan S., Muschal S., Schwager C., Morath C., Wirkner U., Ansorge W. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther 2008, 7:1656-1668.
20. Kim J.H., Scialli A.R. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 2011, 122:1-6.
21. Tiboni G.M., Clementini E. Teratological consequences of nitric oxide synthesis inhibition. Curr Pharm Des 2004, 10:2759-2767.
22. Heike C.L., Hing A.V. Craniofacial microsomia overview. GeneReviews® [Internet] 2009, University of Washington, Seattle, WA. R.A. Pagon, M.P. Adam, H.H. Ardinger, T.D. Bird, C.R. Dolan, C.T. Fong (Eds.).
23. Opitz J.M. The developmental field concept. Am J Med Genet 1985, 21:1-11.
24. Cousley R.R., Wilson D.J. Hemifacial microsomia: developmental consequence of perturbation of the auriculofacial cartilage model?. Am J Med Genet 1992, 42:461-466.
25. Werler M.M., Sheehan J.E., Hayes C., Mitchell A.A., Mulliken J.B. Vasoactive exposures, vascular events, and hemifacial microsomia. Birth Defects Res A: Clin Mol Teratol 2004, 70:389-395.
26. Tendron A., Gouyon J.B., Decramer S. In utero exposure to immunosuppressive drugs: experimental and clinical studies. Pediatr Nephrol 2002, 17:121-130.
27. Carey J.C. Where observation is concerned, chance favors only the prepared mind. Obstet Gynecol 2008, 111:479-480.
28. Cellcept: medication guide. Washington, DC:PN US Food and Drug Administration. Available at:. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM170919.pdf.